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Objective Water-pipe and smokeless tobacco use have
been associated with several adverse health outcomes.
However, little information is available on the association
between water-pipe use and heart disease (HD).
Therefore, we investigated the association of smoking
water-pipe and chewing nass (a mixture of tobacco, lime
and ash) with prevalent HD.
Design Cross-sectional study.
Setting Baseline data (collected in 2004–2008) from a
prospective population-based study in Golestan Province,
Iran.
Participants 50 045 residents of Golestan (40–
75 years old; 42.4% men).
Main outcome measures ORs and 95% CIs from
multivariate logistic regression models for the association
of water-pipe and nass use with HD prevalence.
Results A total of 3051 (6.1%) participants reported a
history of HD, and 525 (1.1%) and 3726 (7.5%)
reported ever water-pipe or nass use, respectively. Heavy
water-pipe smoking was signiﬁcantly associated with HD
prevalence (highest level of cumulative use vs never use,
OR=3.75; 95% CI 1.52 to 9.22; p for trend=0.04). This
association persisted when using different cut-off points,
when restricting HD to those taking nitrate compound
medications, and among never cigarette smokers. There
was no signiﬁcant association between nass use and HD
prevalence (highest category of use vs never use,
OR=0.91; 95% CI 0.69 to 1.20).
Conclusions Our study suggests a signiﬁcant
association between HD and heavy water-pipe smoking.
Although the existing evidence suggesting similar
biological consequences of water-pipe and cigarette
smoking make this association plausible, results of our
study were based on a modest number of water-pipe
users and need to be replicated in further studies.
INTRODUCTION
Heart disease (HD), including ischaemic HD (IHD)
and heart failure (HF), is a major cause of morbid-
ity and mortality worldwide, in both high-income
and low- and middle-income countries.1 2 Tobacco
use in the form of cigarette smoking is an estab-
lished IHD risk factor.3 4 An association between
cigarette smoking and HF has also been reported in
several studies,5–8 perhaps mediated partly through
the effect of smoking on IHD, a major risk factor
for HF,9 and partly through other mechanisms.5 6 8
Smoke from another method of smoking tobacco,
water-pipe (also known as hookah, shisha, nargileh
and qalyan)10 also contains many of the same toxic
compounds as cigarettes11–13 and therefore may
increase HD risk. However, as water-pipe use has
historically been limited to rarely studied popula-
tions, such as those in the East Mediterranean,
little data on the relationship of water-pipe use
with HD is available. Of considerable potential
public health concern, the use of water-pipe is
rapidly increasing globally,10 and it is estimated that
100 million people now use water-pipe world-
wide.14 This increase is seen most rapidly among
the youth of the East Mediterranean and Western
countries in Europe and North America.10 15–17
This calls for epidemiological studies of health
effects of water-pipe, including its association with
HD.18
An association between smokeless tobacco use,
another type of tobacco product, and IHD inci-
dence19 20 and mortality19 21 has also been sug-
gested. However, this association has not been
consistent across studies.21 Smokeless tobacco also
seems to be positively associated with HF,22
although studies are sparse.
The Golestan Cohort Study (GCS), a large-scale
prospective study in Golestan Province, northern
Iran, has collected detailed information on life-long
use of water-pipe, nass (a chewing tobacco product,
mixed with lime and ash, which is used locally and
mostly by men),23 risk factors of IHD, and history
of previous diagnosis of HD. The aim of this paper
is to present results for the association of smoking
water-pipe and chewing nass with prevalent HD
using baseline data collected in the GCS.
MATERIALS AND METHODS
The design of the GCS has been described else-
where.23 Brieﬂy, the GCS is a prospective
population-based cohort, primarily designed to
investigate risk factors of upper gastrointestinal
cancers, with the primary goal of recruiting 50 000
healthy individuals (40–75 years old), with equal
numbers of men and women, 20% from urban
areas and 80% of Turkmen ethnicity from eastern
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parts of Golestan Province. A total of 50 045 adults were
enrolled between 2004 and 2008. Eligibility criteria included
permanent residence in the study area and no history of upper
gastrointestinal cancers.
At baseline, trained nurses and physicians conducted
face-to-face interviews using structured questionnaires to collect
data on a large number of variables including age, sex, ethnicity,
education, place of residence, ownership of several appliances,
life-long history of tobacco use (cigarette, water-pipe and nass,
separately), physical activity and past medical history (including
medications and history of hypertension, diabetes and HD, as
well as age at diagnosis of these diseases). Data on tobacco use
included starting and stopping ages and daily amount used in
different time periods, which captured changes in use over time.
Data on alcohol use were also collected, but as alcohol drinking
was negligible among the study participants,23 we did not
include the data in further analyses.
In accord with our earlier publications,24 we calculated a
composite score for wealth by applying multiple correspondence
analysis to appliance ownership data (including bath in the resi-
dence, personal car, motorbike, black and white TV, colour TV,
refrigerator, freezer, vacuum and washing machine). The scores
were categorised in quartiles. Recreational physical activity is
uncommon in this population, particularly in the age range of
the study participants. Therefore, occupational physical activity
is the main source of physical activity. Two questions assessed
occupational physical activity: if the person worked every
month throughout the year, and if intense physical activity was
a part of the daily work. Three levels of occupational physical
activity were deﬁned based on the answers to these questions:
intense physical activity at work, non-intense but regular phys-
ical activity and non-intense irregular physical activity.
Individuals were considered ever tobacco users if they had
used cigarettes, water-pipe, or nass at least once a week for a
period of 6 months or more. We calculated cumulative amount
of cigarette use (as pack-years) using data on duration and quan-
tity of use. As there are no standard units for quantity of water-
pipe or nass use, we considered the frequency and duration of
water-pipe smoking and nass chewing, assuming relatively small
variation in overall exposure per time of use, and calculated
‘water-pipe-years’ and ‘nass-years’ as units of cumulative use,
respectively; 50 nass-years indicates, for example, the use of
nass ﬁve-times per day for 10 years. Participants in our study
could have begun using tobacco after HD diagnosis, at which
point tobacco use could not have contributed to their risk of
this disease. To estimate the potential effect of such ‘irrelevant
exposure’ on our results, we analysed our data using two
approaches. First, we analysed all available data on tobacco use,
regardless of when participants began smoking. Second, we
excluded HD cases who started using tobacco after disease diag-
nosis. As only a small proportion of participants began to use
tobacco products after HD diagnosis and risk estimates were
similar for each approach (see online supplementary table S1),
we report results after excluding cases who began smoking after
HD diagnosis in this manuscript.
Weight and height were measured by trained research staff.
Body mass index (BMI) was calculated by dividing weight (kg)
by the squared value of height (m). In this study, only physicians
measured blood pressure and collected data on past medical
history. Systolic and diastolic blood pressures were obtained
twice from each arm in the sitting position. Participants were
considered to be hypertensive if they used anti-hypertensive
medication or fulﬁlled the criteria of the Seventh Report of the
Joint National Committee on Prevention, Detection, Evaluation
and Treatment of High Blood Pressure (average systolic blood
pressure ≥140 mm Hg, or average diastolic blood pressure
above ≥90 mm Hg).25 Diabetes mellitus was self-reported based
on the following question ‘Have you ever been diagnosed by a
doctor as having diabetes mellitus?’ Participants were also asked
about past cardiac problems using two separate questions: one
was on rheumatic HD; the other question was ‘Have you ever
been diagnosed by a doctor as having angina, infarction, or
HF?’ Our initial intent was to collect data on IHD. However,
we decided to collect data on IHD and HF as a combined entity
because we expected that a substantial proportion of patients
with HD in the study area, particularly in rural areas, would not
be able to distinguish between IHD, HF, and perhaps some
other types of HD. Those with a positive reply to the latter
question were considered to have HD. We also examined medi-
cations typically prescribed to patients with HD or its risk
factors by self-reported HD status (see online supplementary
table S2). To study the effect of misclassiﬁcation due to personal
reporting, in a sub-analysis, we restricted our endpoint to parti-
cipants using nitrate compounds (including medications contain-
ing trinitroglycerin, isosorbide dinitrate and glyceryltrinitrate),
which are typically prescribed as antianginal agents.
Statistical analysis
Numbers and percentages were calculated and presented for cat-
egorical variables, as well as means and SDs for continuous vari-
ables. We used logistic regression models to calculate ORs and
95% CIs for the association between water-pipe, cigarette, and
nass use and HD prevalence. p values for trend were obtained
from logistic regression models by assigning consecutive
numbers to categories within each categorical variable.
Multivariate models were adjusted for age, sex, ethnicity, place
of residence (rural/urban), education level, wealth, physical
activity, BMI, hypertension, self-reported diabetes and cumula-
tive use of the other tobacco products. Results were adjusted for
place of residence (rural/urban), education and wealth because
these are important indicators of socioeconomic status, and
perhaps access to healthcare, in our study region. We adjusted
the results for ethnicity in order to reduce the potential con-
founding effect of lifestyle factors that may have dissimilar dis-
tributions in different ethnic groups, such as dietary habits. Age,
low physical activity, high BMI, hypertension and diabetes are
established risk factors of HD.26–28 All statistical analyses were
performed using STATA statistical software V.11 (Stata
Corporation, College Station, Texas, USA). All reported p values
are two-sided, and p<0.05 was considered to be statistically
signiﬁcant.
RESULTS
Of 50 045 participants, 3051 (6.1%) reported a history of HD.
The average age of all participants was 52.1 (SD, 9.0) years
(table 1). The distribution of prevalent HD was similar in men
and women. The majority of participants (61.4%) had irregular
non-intense physical activity, and mean BMI was 26.7 (SD, 5.5)
kg/m2. Slightly fewer than half of participants (42.5%) had
hypertension, and 6.9% reported diabetes. Traditional risk
factors of IHD, including age, low physical activity, high BMI,
hypertension and diabetes, were all associated with higher HD
prevalence (see online supplementary table S3).
Distribution of water-pipe, cigarette and nass use and their
associations with HD prevalence are shown in table 2. Ever
water-pipe, cigarette and nass use was reported by 1.1%, 17.1%
and 7.5% of participants, respectively. Heavy water-pipe
smoking was signiﬁcantly associated with HD prevalence
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(highest level of cumulative use vs never use, OR=3.75; 95%
CI 1.5 to 9.22; p for trend=0.04 in multivariate adjusted
models). As many water-pipe users in this study were light
water-pipe smokers, ever versus never water-pipe use was not
associated with HD prevalence (OR=1.09; 95% CI 0.80 to
1.48), but moderate-high use (arbitrarily deﬁned as cumulative
use of >50 water-pipe-years) versus never-low use was asso-
ciated with HD prevalence (OR=1.83; 95% CI 1.10 to 3.07).
We examined this association with several other cutpoints for
the cumulative use; with any cutpoint ≥39 water-pipe-years for
the highest use category, the category was associated with HD
(examples are shown in online supplementary table S4). When
we restricted our HD case deﬁnition to participants who used
HD medications containing nitrate compounds at the time of
enrolment, the OR for the highest category of water-pipe use
became slightly stronger in magnitude (4.50; 95% CI 1.24 to
16.36). As cigarette smoking was also associated with HD
prevalence (p for trend <0.001), we further examined water-
pipe use among never cigarette smokers. There was little
overlap between water-pipe and cigarette smoking in our cohort
and the above associations remained similar in these sensitivity
analyses (see online supplementary table S5).
Nass use did not show a statistically signiﬁcant association
with HD prevalence in the overall analysis (highest category of
use vs never-use, OR=0.91; 95% CI 0.69 to 1.20; p for
trend=0.24) (table 2) or among never cigarette smokers (see
online supplementary table S5). The distributions of water-pipe,
cigarette and nass use by covariates are shown in online supple-
mentary tables S6–S8, respectively.
DISCUSSION
This study provides evidence for a statistically signiﬁcant posi-
tive association between water-pipe smoking and HD preva-
lence, while nass use showed no association. As expected,
traditional risk factors for IHD, including age, cigarette
smoking, low physical activity, high BMI, hypertension and a
history of diabetes were also associated with HD.
The majority of studies on water-pipe smoking have evaluated
the prevalence of use and the correlates of initiation and continu-
ation of use. To our knowledge, the only previously published
investigation of water-pipe smoking and HD is an abstract from a
case-control study in Lebanon with 292 incident cases of IHD
and 233 controls, which suggested an association between water-
pipe use and IHD, with an OR (95% CI) of 1.9 (1.2— 2.8) in
Table 1 Distribution of some sociodemographic characteristics and risk factors of IHD in the Golestan Cohort Study, at the baseline by
self-reported HD status*
Characteristics All participants HD cases Participants without HD p Value
Total 50045 (100) 3051 (100) 46993 (100)
Age (years) 52.1 (9.0) 56.9 (9.1) 51.8 (8.9) <0.001
Sex 0.03
Women 28811 (57.6) 1787 (58.6) 27024 (57.5)
Men 21234 (42.4) 1264 (41.4) 19970 (42.5)
Ethnicity <0.001
Non-Turkmen 12792 (25.6) 1022 (33.5) 11770 (25.0)
Turkmen 37253 (74.4) 2029 (66.5) 35224 (75.0)
Place of residence <0.001
Rural 40013 (80.0) 2272 (74.5) 37741 (80.3)
Urban 10032 (20.0) 779 (25.5) 9253 (19.7)
Education <0.001
No School 35118 (70.2) 2298 (75.3) 32820 (69.8)
Primary/middle school 10708 (21.4) 569 (18.6) 10139 (21.6)
High school 3155 (6.3) 133 (4.4) 3022 (6.4)
University 1064 (2.1) 51 (1.7) 1013 (2.2)
Wealth <0.001
Low 14587 (29.1) 814 (26.7) 13773 (29.3)
Low-Medium 10097 (20.2) 599 (19.6) 9498 (20.2)
Medium-High 12348 (24.7) 749 (24.6) 11599 (24.7)
High 13010 (26.0) 889 (29.1) 12121 (25.8)
Physical activity <0.001
Irregular non-intense 30647 (61.4) 2198 (72.2) 28449 (60.7)
Regular non-intense 13536 (27.1) 654 (21.5) 12882 (27.5)
Regular or irregular intense 5695 (11.4) 192 (6.3) 5503 (11.8)
BMI (kg/m2) 26.7 (5.5) 27.7 (5.7) 26.6 (5.4) <0.001
Hypertension† <0.001
Normotensive 28628 (57.5) 1032 (33.9) 27596 (59.0)
Hypertensive 21197 (42.5) 2012 (66.1) 19185 (41.0)
Self-reported diabetes <0.001
Non-diabetic 46591 (93.1) 2481 (81.3) 44110 (93.9)
Diabetic 3454 (6.9) 570 (18.7) 2884 (6.1)
*Figures are the number of participants (percentage), except for age and BMI, for which mean (SD) is presented. Numbers may not add up to the total numbers due to missing data in
some variables. p Values calculated using χ2 tests for categorical variables and Wilcoxon Rank Sum tests for continuous variables.
†Including self-reported hypertension and individuals with high blood pressure at the baseline examination.
BMI, body mass index; HD, heart disease; IHD, ischaemic heart disease.
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unadjusted and 2.2 (0.9 to 5.4) in adjusted models for
ever-water-pipe smokers versus never-smokers.29 This dearth of
information may be partly because the ‘epidemic’ of water-pipe
use is now mainly among young people:10 16 due to the usual
long latency of the health effects of tobacco use, such effects are
not yet common among the majority of people who use water-
pipe. However, there is biological evidence that water-pipe could
cause HD via mechanisms similar to those of cigarette smoking.
Water-pipe smokers are exposed to many of the same toxic com-
pounds as cigarette smokers, and perhaps at higher levels per
puff: each puff from the water-pipe has been reported to deliver
12-times as much smoke as a single cigarette puff.11 Similar nico-
tine levels have been reported in plasma following water-pipe
and cigarette smoking, and carboxyhaemoglobin levels are three-
fold higher after water-pipe than after cigarette use.11 Carbon
monoxide levels following water-pipe smoking are also higher as
compared with cigarette smoking and the majority of the excess
carbon monoxide appears to come from the burning charcoal
used to heat the tobacco.12 Both cigarette and water-pipe
smoking increase nitric oxide concentration in serum.13
A limited number of studies on other health outcomes of
water-pipe smoking have been published;30 31 they also indicate
Table 2 Association between tobacco use and self-reported HD in the Golestan Cohort Study
Tobacco use* All participants (%) HD cases (%) Participants without HD (%) Unadjusted OR (95% CI) Adjusted OR (95% CI)†
Water-pipe smoking
Ever versus never use
Never 49489 (98.9) 2990 (98.1) 46499 (99.0) Reference Reference
Ever 525 (1.1) 51 (1.9) 474 (1.0) 1.67 (1.25 to 2.24) 1.09 (0.80 to 1.48)
Moderate-high versus never-low use
≤50 water-pipe-years 49894 (99.8) 3022 (99.4) 46872 (99.8) Reference Reference
>50 water-pipe-years 120 (0.2) 19 (0.6) 101 (0.2) 2.92 (1.78 to 4.77) 1.83 (1.10 to 3.07)
Cumulative use
Never 49489 (98.9) 2990 (98.3) 46499 (99.0) Reference Reference
≤50 water-pipe-years 405 (0.8) 32 (1.0) 373 (0.8) 1.33 (0.93 to 1.91) 0.87 (0.60 to 1.28)
50.1–100 52 (0.1) 6 (0.2) 46 (0.1) 2.03 (0.86 to 4.74) 1.25 (0.52 to 3.03)
100.1–180 43 (0.1) 5 (0.2) 38 (0.1) 2.05 (1.03 to 2.80) 1.49 (0.57 to 3.87)
>180 25 (0.1) 8 (0.3) 17 (0.04) 6.39 (2.65 to 15.41) 3.75 (1.52 to 9.22)
p trend: <0.001 p trend: 0.04
Cigarette smoking
Ever versus never use
Never 41445 (82.9) 2405 (79.7) 39040 (83.1) Reference Reference
Ever 8555 (17.1) 614 (20.3) 7941 (16.9) 1.26 (1.14 to 1.38) 1.63 (1.45 to 1.83)
Moderate-high versus never-low use
≤5 pack-years 44187 (88.4) 2559 (85.3) 41628 (88.6) Reference Reference
>5 pack-years 5813 (11.6) 460 (14.7) 5353 (11.4) 1.40 (1.26 to 1.55) 1.76 (1.55 to 1.99)
Cumulative use
Never 41445 (82.9) 2405 (79.7) 39040 (83.1) Reference Reference
≤5 pack-years 2742 (5.5) 154 (5.1) 2588 (5.5) 0.97 (0.82 to 1.14) 1.26 (1.05 to 1.52)
5.1–10 1260 (2.5) 73 (2.4) 1187 (2.5) 1.00 (0.79 to 1.27) 1.43 (1.11 to 1.84)
10.1–20.0 1798 (3.6) 121 (4.0) 1677 (3.6) 1.17 (0.97 to 1.41) 1.73 (1.41 to 2.13)
>20 2755 (5.5) 266 (8.8) 2489 (5.3) 1.73 (1.52 to 1.98) 2.04 (1.74 to 2.38)
p trend: <0.001 p trend: <0.001
Nass chewing
Ever versus never use
Never 46264 (92.5) 2775 (92.5) 43489 (92.5) Reference Reference
Ever 3726 (7.5) 225 (7.5) 3501 (7.5) 1.01 (0.88 to 1.16) 0.85 (0.73 to 1.00)
Moderate-high versus never-low use
≤50 nass-years 48026 (96.1) 2859 (95.3) 45167 (96.1) Reference Reference
>50 nass-years 1964 (3.9) 141 (4.7) 1823 (3.9) 1.22 (1.03 to 1.46) 0.95 (0.79 to 1.15)
Cumulative use
Never 46264 (92.5) 2775 (92.5) 43489 (92.5) Reference Reference
≤50 nass-years 1762 (3.5) 84 (2.8) 1678 (3.6) 0.78 (0.63 to 0.98) 0.75 (0.60 to 0.95)
50.1–100 635 (1.3) 43 (1.4) 592 (1.3) 1.14 (0.83 to 1.56) 0.98 (0.71 to 1.36)
100.1–180 532 (1.1) 35 (1.2) 497 (1.0) 1.10 (0.78 to 1.56) 0.90 (0.62 to 1.28)
>180 797 (1.6) 63 (2.1) 734 (1.6) 1.35 (1.04 to 1.74) 0.91 (0.69 to 1.20)
p trend: 0.09 p trend: 0.24
Numbers may not add up to the total numbers due to missing data in some variables.
*Among HD cases, those who started the use of the tobacco product after receiving a diagnosis of HD were excluded from the analyses related to the respective product; 100
water-pipe-years, for example, indicates water-pipe use equivalent to use 10 times per day for 10 years (or use 5 times per day for 20 years).
†All results for each tobacco product were adjusted for cumulative use of the other products listed in this table, as well as for age, sex, ethnicity, place of residence, education level,
wealth, physical activity, body mass index, hypertension, and self-reported diabetes (these variables were as shown in Table 1).
HD, heart disease.
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harmful health effects. Current evidence suggests an association
between water-pipe use and respiratory illness, lung cancer, low
birth-weight and periodontal disease.30 31 A more limited
number of studies have also suggested associations between
water-pipe smoking and risk of upper aerodigestive tract neopla-
sia32 33 and bladder cancer.34 35
Several methodological considerations are of potential
concern. Cross-sectional analyses may be subject to bias due to
reverse causality. For example, one might argue that after receiv-
ing a diagnosis of HD, patients may replace cigarette smoking
with water-pipe use. To avoid this problem, we excluded from
analysis HD patients who started using water-pipe after receiv-
ing a diagnosis of HD. Diagnosis of HD was based on partici-
pants’ reports, which could be misclassiﬁed. Such
misclassiﬁcation, if non-differential with respect to water-pipe
use, would lead to results that are biased toward null,36 not
away from null. Therefore, non-differential misclassiﬁcation
cannot explain our ﬁnding of an increased risk of HD in rela-
tion to water-pipe use. In fact, when we limited our case deﬁn-
ition to cases using nitrate compounds, the risk estimates
strengthened, supporting our hypothesis. Differential misclassiﬁ-
cation is also possible if there was residual confounding after
adjustments, as water-pipe users—people with lower wealth and
education—may be less aware of their HD. Such misclassiﬁca-
tion, however, would also shift our ﬁndings towards a null or an
inverse association, and as such would have resulted in the
attenuation of our risk estimates. Using prevalence ratios, rather
than incidence ratios, may lead to what has been called
incidence-prevalence bias,37 but since water-pipe use is unlikely
to expand longevity, prevalence ratios would be either equal to
or underestimations of incidence ratios. Finally, analyses using
different cutpoints for the highest category of water-pipe use all
showed an increased risk of HD.
One limitation of our study is a lack of speciﬁcity in our assess-
ment of HD. Prior history of angina, infarction, or HF was asked
as a single question, because we did not expect participants in our
study would be able to distinguish between IHD, HF, or other
types of HD. As these data were collected by interactive
face-to-face interviews conducted by trained researcher physicians,
it is unlikely that many cases of HDs other than IHD and HF were
categorised as HD cases in this study. Although little information
is available on the relative prevalence of IHD and HF in Iran, we
would nevertheless expect that a majority of cases are IHD. In the
most recent available national mortality data from Iran (2004),
IHD The International Classiﬁcation of Diseases (ICD10 codes
I20 to I25) was the cause of 21.8% of all mortality cases in Iran,
approximately 7-times more than hypertensive HD (ICD 10 codes
I10 to I13, which included heat failure), which was the cause of
death in 3.2% of cases.38 Similarly, in the few available reports on
incidence in Iran, HF was associated with IHD in 60–65% of
admitted patients,39 40 with similar proportions observed in
studies from adjacent countries (40–60%),41–45 and those from
the West.5 46 Furthermore, we analysed medication use in our
study and observed that only 5% of our cases used digoxin, a
medication commonly prescribed for symptomatic HF,47 48 and
even among those using digoxin, one-third also used nitrate com-
pounds, indicated for IHD. Therefore, we believe that IHD is far
more common than HF in this study, and that a considerable pro-
portion of HF patients also had IHD. However, further studies on
the association of water-pipe use with IHD, HF, and other forms
of HD are needed.
Regardless of the exact diagnosis (IHD, HF, or other), our
results suggest potentially harmful effects of water-pipe smoking
on cardiac structure and function. The prevalence of water-pipe
use in our study was 1%, substantially lower than rates of use
among young people globally.10 In the USA, for example, 5–
20% of college students have reported water-pipe use over the
past month.17 Therefore, if associations are causal, water-pipe
use may cause many cases of HD and other tobacco-related dis-
eases in the coming decades, should use continue at current or
higher levels.
In our study, we observed no evidence for an association
between nass use and HD. Whereas studies from Sweden gener-
ally have not shown an association between smokeless tobacco
(mainly snus) use and IHD incidence, some US studies and a
multicentre study in 52 countries (the INTERHEART Study,
with various smokeless tobacco products) have shown positive
associations.19 20 Variations across studies may be related to the
type of smokeless tobacco product used (eg, snuff, snus and
many chewing products), differences in use across populations
and methodological differences between studies.21
The null association between nass chewing and prevalent HD
in our study may be true, but residual confounding cannot be
ruled out. Nass chewing is far more common in rural than in
urban areas of Golestan, and due to lower access to advanced
medical care centres, the rate of undiagnosed subclinical cases
of HD in rural areas of Golestan may be higher than in urban
areas. However, we adjusted for rural/urban residence, and pat-
terns of residence in the age range of our study participants are
relatively stable and easily measurable. Therefore, substantial
residual confounding due to residence is unlikely. Nass chewing
was also more common among those with lower wealth and
education, people who may be less likely to be aware of their
HD. If residual confounding exists, the estimated risk ratios
would be falsely low. It should also be noted that nass is not a
pure tobacco product, and lime and ash, with probably varied
constituents, are also mixed with tobacco. Further studies on
the association between nass chewing—and its constituents—
and HD are warranted.
In our study, similar to previous literature, traditional IHD
risk factors, including age, cigarette smoking, low physical activ-
ity, high BMI, hypertension and diabetes were associated with
HD prevalence. As these associations have been reviewed in a
number of publications,26–28 we do not elaborate on them here.
The strengths of this study include relatively high participa-
tion rates, collection of detailed lifetime information on differ-
ent types of tobacco products using a validated questionnaire,49
and adjustments for several potential confounders. We were also
able to investigate the association between water-pipe use and
HD among never cigarette smokers. On the other hand,
although this study, with approximately 3000 HD cases and
47 000 controls, represents the largest published study on the
association between water-pipe smoking and HD, the number
of water-pipe users among HD cases was relatively small, thus
limiting the precision of the estimates. We also lacked informa-
tion on blood cholesterol levels. Cigarette smoking may cause
IHD by lowering high density lipoprotein cholesterol or by
exacerbating the effects of low density lipoprotein choles-
terol.50–52 However, cholesterol level would be a mediator not a
confounder; as blood cholesterol levels are unlikely to modulate
the prevalence of water-pipe smoking, any spurious association
between water-pipe use and HD as a result of confounding
effect of cholesterol levels is not expected. Other potential lim-
itations, including the cross-sectional nature of the study, self-
report of outcomes, and inability to distinguish between differ-
ent types of HD, have been discussed above.
In conclusion, we found a statistically signiﬁcant association
between heavy water-pipe smoking and HD. Although this
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association was based on a modest number of water-pipe users,
similarity in the constituents and biological consequences of
water-pipe and cigarette smoke provide plausibility. However,
the observed association needs to be replicated in other popula-
tions. Future studies are also needed to evaluate the associations
of water-pipe use, cancer, and other diseases. The growing body
of evidence linking water-pipe smoking to chronic disease,
coupled with a worldwide increase in prevalence of water-pipe
use in young people, is of particular public health concern and
may warrant prevention and control measures.
Key messages
We found a statistically signiﬁcant association between
water-pipe smoking and ischaemic heart disease. Future studies
are also needed to evaluate the associations of water-pipe use,
cancer and other diseases. The growing body of evidence
linking water-pipe smoking with chronic disease and increasing
prevalence of water-pipe use among young people are of
particular public health concern and may warrant prevention
and control measures.
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